辛伐他汀联合阿昔莫司治疗混合型高脂血症的疗效与安全性研究  

Studies on efficacy and safety of simvastatin plus acipimox for treating combined hyperlipidemia

作　　者：骆雷鸣[1] 叶平[1] 朱启伟[1] 张灵[1] 朱兵[1] 杨雪[1] 史军[1] 张明华[1] 刘国树[1] 

机构地区：[1]解放军总医院南楼心血管二科,北京100853

出　　处：《药物不良反应杂志》2007年第3期158-161,共4页Adverse Drug Reactions Journal

摘　　要：目的:评价辛伐他汀联合阿昔莫司治疗混合型高脂血症的疗效及安全性。方法:入选63例冠心病合并混合型高脂血症的患者,随机分为2组:辛伐他汀+阿昔莫司组(32例)和辛伐他汀组(31例)。2组患者均接受正规的抗心肌缺血治疗,辛伐他汀+阿昔莫司组给予辛伐他汀20mg/d,阿昔莫司500mg/d;辛伐他汀组给予辛伐他汀20mg/d,均连续治疗3个月。比较2组治疗前后血脂各项指标变化,并记录药物不良反应。结果:2组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)均较治疗前下降,辛伐他汀+阿昔莫司组TC、LDL-C、TG下降更为显著,并伴高密度脂蛋白胆固醇(HDL-C)升高。辛伐他汀+阿昔莫司组除皮肤反应发生率较高外,其他不良反应发生率2组相近。结论:辛伐他汀联合阿昔莫司能降低LDL-C和TC,并能升高HDL-C,是治疗混合型高脂血症的安全有效的疗法。Objective： To evaluate the efficacy and safety of simvastatin plus acipimox for treating combined hypedipidemia. Methods： Sixty-three patients with coronary heart disease and combined hyperlipidemia were divided into the following two groups： simvastatin plus acipimox group（32 cases） and simvastatin group（31 cases）. All patients in the two groups were receiving anti-ischemia therapy. The patients in simvastatin plus acipimox group were administered with simvastatin 20 mg/day and acipimox 500 mg/day. The patients in simvastatin group were administered with simvastatin 20 mg/day. The duration of treatment was 3 months. The changes in serum lipid concentrations were compared between the two groups before and after the treatment. The adverse reactions were recorded.. Results. After treatment, the levels of the serum total cholesterol（TC）, low density lipoprotein cholesterol（LDL-C）, and triglyceride（TG） were decreased in two groups. But in simvastatin plus acipimox group, they were significantly decreased, and the high density lipoprotein cholesterol（HDL-C） level was increased. The incidence of adverse reactions in the two groups were similar, except the skin reactions were more frequent in simvastatin plus acipimox group. Conclusion. The regimen of simvastatin plus acipimox is capable of lowering LDL-C, TC, and raising HDL-C. It is an effective and safe therapy in treatment of combined hyperlipidemia.

关 键 词：混合型高脂血症 辛伐他汀 阿昔莫司 不良反应 

分 类 号：R589.2[医药卫生—内分泌]